Literature DB >> 7072807

The clearance of intravitreal triamcinolone acetonide.

R H Schindler, D Chandler, R Thresher, R Machemer.   

Abstract

Since high corticosteroid levels are important in achieving inhibition of intraocular cellular proliferation, we studied the clearance of an intravitreally injected slowly dissolving corticosteroid in the rabbit eye. Triamcinolone acetonide (0.5 mg) disappeared rapidly in eyes that underwent a combined vitrectomy and lensectomy (average, 6.5 days) and more slowly in eyes that underwent vitrectomy only (average, 16.8 days) compared with unoperated normal rabbit eyes (average, 41 days). The ophthalmoscopic disappearance of the white crystals correlated well with a sensitive colorimetric test for clearance of the corticosteroid. Direct observation is therefore an accurate method of assessing the absorption of the corticosteroid. If used therapeutically, this study suggests that more frequent injections of triamcinolone acetonide would be necessary in eyes that underwent vitrectomy, compared with normal eyes.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7072807     DOI: 10.1016/0002-9394(82)90130-1

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  42 in total

1.  Intraocular pressure after intravitreal injection of triamcinolone acetonide.

Authors:  J B Jonas; I Kreissig; R Degenring
Journal:  Br J Ophthalmol       Date:  2003-01       Impact factor: 4.638

2.  Concentration of intravitreally injected triamcinolone acetonide in aqueous humour.

Authors:  Jost B Jonas
Journal:  Br J Ophthalmol       Date:  2002-09       Impact factor: 4.638

3.  Pharmacokinetics and safety of intravitreally delivered etanercept.

Authors:  Sascha Fauser; Hubert Kalbacher; Nils Alteheld; Kan Koizumi; Tim U Krohne; Antonia M Joussen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-03-17       Impact factor: 3.117

Review 4.  [Ocular side effects and complications of intravitreal triamcinolone acetonide injection].

Authors:  G B Jaissle; P Szurman; K U Bartz-Schmidt
Journal:  Ophthalmologe       Date:  2004-02       Impact factor: 1.059

5.  Influence of different purification techniques on triamcinolone yield and particle size spectrum.

Authors:  Peter Szurman; Radoslaw Kaczmarek; Gesine B Jaissle; Salvatore Grisanti; Matthias Lüke; Martin S Spitzer; Peter-Edgar Heide; Karl U Bartz-Schmidt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-09-28       Impact factor: 3.117

6.  Photographic estimation of the duration of high dose intravitreal triamcinolone in the vitrectomised eye.

Authors:  B R Kosobucki; W R Freeman; L Cheng
Journal:  Br J Ophthalmol       Date:  2006-03-10       Impact factor: 4.638

7.  RANIBIZUMAB PLUS PROMPT OR DEFERRED LASER FOR DIABETIC MACULAR EDEMA IN EYES WITH VITRECTOMY BEFORE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.

Authors:  Susan B Bressler; Michele Melia; Adam R Glassman; Talat Almukhtar; Lee M Jampol; Michel Shami; Brian B Berger; Neil M Bressler
Journal:  Retina       Date:  2015-12       Impact factor: 4.256

Review 8.  [Retinal vein occlusions].

Authors:  S Dithmar; L L Hansen; F G Holz
Journal:  Ophthalmologe       Date:  2003-07       Impact factor: 1.059

9.  [Intravitreal administration of triamcinolone and bevacizumab for pigment epithelial detachment in conjunction with AMD].

Authors:  A Frimpong-Boateng; M A Varde; F Rüfer; A Bunse; J Roider
Journal:  Ophthalmologe       Date:  2008-07       Impact factor: 1.059

10.  Comparison of photocoagulation with combined intravitreal triamcinolone for diabetic macular edema.

Authors:  Ho Young Lee; Seung Yong Lee; Jong Seok Park
Journal:  Korean J Ophthalmol       Date:  2009-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.